Fabrication of Anisotropic Polymeric Artificial Antigen Presenting Cells for CD8+ T Cell Activation
October 12th, 2018
Here, we present a protocol to quickly and reproducibly generate biologically inspired, biodegradable articifical antigen presenting cells (aAPC) with tunable size, shape, and surface protein presentation for T cell expansion ex vivo or in vivo.
Overview
This article presents a protocol for generating biodegradable artificial antigen presenting cells (aAPC) with customizable properties for T cell expansion. The method offers insights into the role of particle characteristics in immune cell interactions and has implications for cancer therapy and other diseases.
Key Study Components
Area of Science
- Biomaterials
- Immunology
- Cancer therapy
Background
- Biologically inspired particles can enhance immune responses.
- Control over particle size and shape is crucial for biomimetic applications.
- This method can be applied to various therapeutic contexts.
- Understanding immune cell interactions is essential for developing effective therapies.
Purpose of Study
- To develop a reproducible method for creating aAPC.
- To explore the effects of particle properties on immune activation.
- To provide a versatile platform for cancer and other disease therapies.
Methods Used
- Protocol for generating aAPC with tunable characteristics.
- Assessment of immune cell interactions with biomimetic particles.
- Evaluation of in vivo immune responses.
- Application of the method to various disease models.
Main Results
- Demonstrated independent control over size and shape of particles.
- Showed enhanced immune activation in response to aAPC.
- Validated the method's applicability in cancer therapy.
- Highlighted potential uses in infectious diseases and Type One diabetes.
Conclusions
- The developed protocol is a valuable tool for immunotherapy research.
- Insights gained can inform future therapeutic strategies.
- This method represents a significant advancement in biomaterial design.
Frequently Asked Questions
Executive Industry Relevance
This protocol enables reproducible fabrication of anisotropic polymeric artificial antigen presenting cells (aAPC) with independent control over size and shape, addressing a key challenge in biomaterial design for immunotherapy. By providing a scalable, off-the-shelf platform for T cell activation, it supports preclinical development of cancer immunotherapies and other immune-mediated diseases. The method enhances predictive confidence in early discovery by linking particle anisotropy to functional immune outcomes, facilitating go/no-go decisions in pipeline advancement.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of how particle physical properties influence T cell activation and immune synapse formation.
- Operational Value: Provides standardized, reproducible aAPC production for consistent functional assays across discovery campaigns.
Screening & Assay Development
- Scientific Value: Generates anisotropic aAPC with tunable signal presentation for dose-dependent T cell proliferation readouts.
- Operational Value: Supports scalable production of micro- and nano-scale aAPC for high-throughput immune screening platforms.
Translational & Preclinical Research
- Scientific Value: Demonstrates enhanced T cell stimulation by prolate ellipsoidal aAPC versus spherical counterparts at sub-saturating doses.
- Operational Value: Enables in vivo administration to assess therapeutic efficacy and pharmacokinetics in disease models.
Pipeline & Workflow Integration
The method fits within the discovery continuum from early target validation through preclinical immune response assessment, supporting iterative design of immunomodulatory biologics.
- Discovery Biology: Supports hypothesis testing on how anisotropy affects immune cell binding, activation, and downstream signaling.
- Screening: Delivers quantitative, reproducible T cell proliferation outputs for comparing particle formulations.
- Analytics: Provides measurable outputs including aspect ratio, conjugation efficiency, and immune activation levels for structure-function analysis.
- Translational Research: Connects in vitro T cell expansion data to in vivo therapeutic evaluation in cancer and autoimmune models.
- Enterprise Reuse: Establishes a reusable platform for generating off-the-shelf aAPC across multiple immunotherapy programs.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in T cell activation through mechanistic de-risking of particle shape effects.
- Operational Value: Standardized, scalable fabrication with wash-and-resuspend protocols ensuring batch-to-batch consistency.
- Strategic Value: Enables risk-adjusted prioritization of anisotropic versus spherical aAPC candidates based on immune stimulation data.
- Portfolio Impact: Supports advancement decisions by linking particle design to functional immune outcomes in relevant disease models.
Implementation Considerations
- Expertise in biomaterials synthesis, particle engineering, and immunoassay techniques.
- Access to homogenization, sonication, stretching equipment, and centrifugation infrastructure.
- Standardization of film casting, stretching parameters, and protein conjugation protocols across teams.
- Adaptation considerations for scaling micro- versus nano-particle production while maintaining anisotropy.
- Practical limitations include solvent handling requirements and need for precise environmental control during film drying and stretching.
Biopharma FAQs
Chapters in this video
0:04
Title
0:49
Tunable Spherical Poly(Lactic-Co-Glycolic Acid) (PLGA) Fabrication
3:30
Tunable Polymeric Particle Fabrication
6:21
Surface Protein Conjugation for Artificial Antigen Presenting Cell (aAPC) Creation
8:01
Results: Representative Spherical and Ellipsoidal Particle Characterization
9:49
Conclusion
